Benzinga | Dec 13, 2021 09:52AM EST

RBC Capital Initiates Coverage On Prometheus Biosciences with Outperform Rating, Announces Price Target of $46

RBC Capital analyst Gregory Renza initiates coverage on Prometheus Biosciences (NASDAQ:RXDX) with a Outperform rating and announces Price Target of $46.